A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

Results from the DESTINY-CRC02 study showed that the lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.

Results from the TALAPRO-2 study highlight the potential for the first-line treatment of patients with homologous recombination repair alliterated metastatic castration-resistant prostate cancer.

When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

ADAURA is the first global phase 3 study to demonstrate statistically significant and clinically meaningful disease-free survival and overall survival benefit with adjuvant targeted therapy for patients with EGFR-mutated, stage IB to IIIA NSCLC.

Further dose optimization is ongoing in the phase 1 study of BI 764532 following the read-out of positive results.

At the second planned interim analysis of the Phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

The first study of a dual bispecific combination in relapsed or refractory multiple myeloma encourages the investigators.

Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.

Positive results have been reported from phase 1/2 KEYMAKER-U03B study, and belzutifan plus lenvatinib is being further investigated in the phase 3 LITESPARK-011 study (NCT04586231).

TALAPRO-2 is the first phase 3 study to evaluate talazoparib plus enzalutamide as a first-line treatment in patients with metastatic castration resistant prostate cancer.

An update from the phase 3 NAPOLI 3 trial supports the use of NALIRIFOX for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

The FDA is no longer concerned about the safety of MT-0169, and the developer of the agent plans to focus its effort on the extramedullary myeloma population.

According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

ACTION-1 is investigating RYZ101 versus standard-of-care therapy in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors after 177Lu-SSA therapy.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.